CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  About Us  /  Fact Sheet

FACT SHEET

Biocon

We are a global biopharmaceutical company driven by the belief that everyone, everywhere deserves access to affordable, quality medicines. At Biocon, we pioneer novel approaches to improve patient outcomes today, for a better tomorrow. We constantly find new ways to treat diabetes, cancer and autoimmune diseases to improve the quality of life for an ageing population.

Biocon Biologics

A subsidiary of Biocon, Biocon Biologics’ cutting-edge R&D and global scale manufacturing have provided an innovative portfolio of approved and in-development life-changing biosimilars. Three of these biosimilars have received global acclaim with commercialisation in the EU, U.S., Japan and Australia. It has provided over 2 billion doses of human insulin worldwide, making it a leading global insulins provider.

Syngene

Syngene is Biocon’s global innovation-focussed subsidiary that specialises in integrated scientific services. It delivers world-class solutions across the drug discovery and development continuum to pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world.

Biocon At A Glance

Making affordable healthcare
accessible to all

Quick Facts

FACTSHEET

Advancing biotechnology for 40+ years

Improving lives across 120+ countries

Talented, dedicated workforce of 12,000+ employees

OUR BUSINESSES

OUR BUSINESSES

biocon-factsheet-04

Generics

biocon-factsheet-05

Biosimilars

biocon-factsheet-06

Research Services

biocon-factsheet-07

Novel Biologics

KEY THERAPEUTIC AREAS

KEY THERAPEUTIC AREAS

DIABETES

We help people with diabetes manage their health more effectively and comfortably through our high quality, affordable biosimilar insulins. We are a leading global biosimilars player in recombinant human insulin and Insulin Glargine and also among a handful of global players working on a novel oral insulin molecule.

ONCOLOGY

We transform the lives of people with cancer through our affordable world-class cancer care therapies. We are at the forefront of finding cures for cancer and have introduced transformational life-saving cancer therapies – both biosimilars and novel biologics – in India. We are now focused on making this high-quality cancer treatment affordable for the global patient population.

IMMUNOLOGY

We aim to deliver innovative therapies for patients suffering from autoimmune diseases to help them manage these lifelong ailments better. We are working on bringing safe, efficacious, affordable immune-modulator medicines to treat patients coping with these immune-related disorders.

A CULTURE OF INNOVATION

A CULTURE OF INNOVATION

biocon-factsheet-11
0
Patents Granted (Small Molecules)
biocon-factsheet-11
0
Patents Granted (Biologics)
biocon-factsheet-12
0
+
cGMP Approvals international regulatory agencies
biocon-factsheet-13
0
Biologics were taken from 'Lab to Market': 2 Novels and 5 Biosimilars

MANUFACTURING

SUBSIDIARIES

One of India’s largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices

The largest integrated insulin manufacturing and R&D facility in Malaysia

Biocon Biologics develops high quality, affordable biosimilars

One of India’s largest biomanufacturing facilities for insulins, monoclonal antibodies and devices

Set up Asia’s largest integrated Insulin manufacturing and R&D facility in Malaysia

Syngene, India’s first custom research organisation CRO From lead generation to clinical supplies

Internationally reputed CRO and manufacturing organisation

Clientele: Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife

OUR REVENUES

OUR REVENUES

GLOBAL EMPLOYEE BASE

GLOBAL EMPLOYEE BASE

A LEADER AND TRAILBLAZER

A LEADER AND TRAILBLAZER

FIRST

First listed ‘pure play’ bio-pharmaceuticals company in India

First to launch an ingenuously developed novel biologic in India

First company from India to have a biosimilar commercialised in the U.S and in Japan

Developed and launched Itolizumab – the world’s first novel anti-CD6 monoclonal antibody

LEADER

One of the largest statins manufacturers in the world, supplying drug substances to over 60 countries

One of the largest producers of immunosuppressant APIs globally

Preferred APIs partner for over 1,000 pharma companies in more than 100 countries

Among the largest biologics manufacturing capacity in India

Set up Asia’s largest integrated insulins manufacturing complex in Malaysia

Among the leading insulins players globally

Among Top 10 Global Biotech Employers as ranked by prestigious US-based Science magazine

BEST

Bringing safe, efficacious, affordable immune-modulator medicines to treat immune related disorders and help patients manage their lives better

FINANCIAL CALENDAR
BIOCON FOUNDATION  
MEET OUR EMPLOYEES 
OUR CULTURE
MEDIA STORIES
Share